In Vitro and in Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-16-0251
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Acute Myeloid Leukemia Stem Cells and CD33-targeted Immunotherapy

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Preclinical Efficacy of a PSMA-targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

High CD33-antigen Loads in Peripheral Blood Limit the Efficacy of Gemtuzumab Ozogamicin (Mylotarg®) Treatment in Acute Myeloid Leukemia Patients

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2004English

In-Vivo Comparison of Thorium-227 and Zirconium-89 Labeled 3,2-Hopo Mesothelin Antibody-Chelator Conjugate

Journal of Medical Imaging and Radiation Sciences
RadiologicalRadiologyNuclear MedicineUltrasound TechnologyImaging
2019English

Novel Immunotherapeutic Approaches for the Treatment of Acute Leukemia (Myeloid and Lymphoblastic)

Therapeutic Advances in Hematology
Hematology
2015English

CT-721, a Potent BCR-Abl Inhibitor, Exhibits Excellent in Vitro and in Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia

Journal of Cancer
Oncology
2017English

A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia

Frontiers in Pharmacology
Pharmacology
2019English

Novel Targeted Drug Therapies for the Treatment of Childhood Acute Leukemia

Expert Review of Hematology
Hematology
2009English

Distribution and Levels of Cell Surface Expression of CD33 and CD123 in Acute Myeloid Leukemia

Blood Cancer Journal
OncologyHematology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy